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Abstract
Forkhead box O1 (FOXO1) is upregulated during bone formation and in response to stimulation
by bone morphogenetic proteins. Studies presented here examined the functional role of FOXO1
in a well defined culture system in which pre-osteoblastic cells undergo terminal differentiation in
vitro. Mineralizing cultures of MC3T3-E1 cells were examined with or without FOXO1
knockdown by RNAi. Normal cells show the upregulation of FOXO1 and RUNX2 DNA binding
activity, alkaline phosphatase activity, and mRNA levels of FOXO1, RUNX2, type 1 collagen,
osteocalcin and MMP13 during formation of mineralizing nodules. In FOXO1 depleted cells each
of these measurements was significantly reduced compared to values in control cells transfected
with scrambled siRNA (P< 0.05). Depletion of FOXO1 also reduced the number of mineralized
nodules formed. Moreover, chromatin immunoprecipitation assays revealed a direct interaction of
FOXO1 with the RUNX2 promoter. Overexpression of FOXO1 reduced MC3T3-E1 cell number
and the number of PCNA positive cells with little effect on apoptosis. These findings indicate that
FOXO1 plays an important role in promoting osteoblast differentiation and suppressing
proliferation in differentiating cells.
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Introduction
Osteoblasts are bone forming cells that are responsible for mineralization of the organic
matrix [1]. The commitment of the differentiation of mesenchymal cells to osteoblasts is an
important aspect of skeletal development and bone growth. Bone formation is a well
organized process that involves recruitment of pluripotent mesenchymal cells, commitment,
proliferation, growth arrest and osteoblast differentiation [2]. Osteoblast differentiation is
controlled by external signals that induce a cascade that results in terminally differentiated
osteoblasts [3]. Bone morphogenetic proteins are important members of the TGF-β
superfamily which stimulate the migration and proliferation of mesenchymal progenitors, as
well as commitment into the chondrogenic, osteogenic or adipogenic lineage. For example,
low concentrations of BMP2 favour adipocyte differentiation and, in contrast, high
concentrations of BMP2 favor chondrocyte and osteoblast differentiation [4, 5]. BMP2
works through the activation of SMADs which regulate the transcription of osteogenic genes
such as Runt-related transcription factor 2 (RUNX2) [6]. RUNX2 determines the lineage of
osteoblasts from multipotent mesenchymal cells, inducing osteoblast differentiation at early
stages [7, 8]. RUNX2 has been shown in numerous studies to be crucial for osteoblast
differentiation by regulating the expression of various osteoblastic genes such as type I
collagen, osteopontin, and osteocalcin [8].
A potentially important transcription factor in regulating formation of a mineralizing matrix
is forkhead-01 (FOXO1), a member of the forkhead-O family of transcription factors that
include FOXO1, FOXO3, FOXO4 and FOXO6 [9]. FOXO1 and FOXO3 in particular have
similar functions and are present in a wide range of cellular and developmental processes
[9]. FOXO1 is activated in bone lining cells under conditions of inflammation and mediates
cytokine induced apoptosis of osteoblastic cells [10]. A linkage between FOXO1 and
osteoblast activity has been suggested indirectly by evidence that BMP-2 induces a two fold
increase in FOXO1 mRNA levels in human mesenchymal stem cells, and that transfection
of FOXO1 increased the reporter activity of an alkaline phosphatase promoter construct [11,
12]. More recently FOXO1 has been shown to play an important role in bone formation in
vivo, although the mechanism through which this occurs has not been settled. In one
publication, genetic deletion of FOXO1 suggested that FOXO1 promotes bone formation by
modulating proliferation of osteoblastic precursors but not by affecting differentiation [13].
In another publication, deletion of FOXO1, FOXO3 and FOXO4 suggested that these
factors promote bone formation in part by modulating differentiation of osteoblastic cells
[14]. It is possible that deletion of FOXO1 alone led to compensatory changes in vivo,
accounting for the difference in phenotype. To clarify the role of FOXO1 in differentiation,
we undertook experiments to study the effects of FOXO1 knockdown on the formation of
mineralizing cultures in vitro with particular attention to the impact on RUNX2.
Methods
Cell Culture
MC3T3-E1 cells (murine osteoblastic cells) were purchased from ATCC (Rockville, MD)
and grown in α-MEM (HyClone, South Logan, UT) containing 10% fetal bovine serum
(FBS) (Atlanta Biologicals, Atlanta, GA), 1% Penicillin/Streptomycin (Cellgro, Manassas,
VA) and 1% non-essential amino acids (Cellgro) at 37° C in a humidified atmosphere of 5%
CO2 in air. To induce mineralization, the media was supplemented with 50 μg/ml of
ascorbic acid (Fisher Biotech, Waltham, MA) and 10 mM of β-glycerolphosphate
(Invitrogen, Carlsbad, CA) as described elsewhere [15]. In time course experiments day 0
was defined as the time just prior to incubation in mineralizing media and cells were
incubated for up to 21 days in mineralizing media.
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Chromatin Immunoprecipitation
Chromatin immunoprecipitation assays were performed with the EZ ChIP™ system
(Upstate Cell Signaling Solutions, Lake Placid, NY), according to manufacturer's directions,
modified to include pre-clearing of lysates with 60 μl of a 50% slurry of protein G/salmon
sperm DNA for 1hr at 4° C, and again overnight. The Runx2 promoter primer sequences
used were Fwd: AACCTTCTGAATGCCAGGAA and Rev:
GTGGGACTGCCTACCACTGT. FOXO1 and SP1 specific antibodies and control IgG
were obtained from Santa Cruz Biotechnology, INC. (Santa Cruz). PCR was performed for
40 cycles at 30s at 95°C, 30s at 72°C and 30s at 55°C.
Transient Transfection
MC3T3-E1 cells were plated in 6 well plates and cultured for 2 days in mineralizing media.
Transfection was carried out in cells approximately 70% confluent with the use 5 nM
FOXO1 siRNA (target sequence: CCA GCT ATA AAT GGA CAT TTA) or scrambled
siRNA (Qiagen, Valencia, CA) in media containing 0.35% FBS and HiPerFect Transfection
Reagent (Qiagen) for 24 hours and then changed to standard mineralizing media. For
mineralized nodules formation, MC3T3-E1 cells were transfected with FOXO1 siRNA or
scrambled siRNA without previous exposure to mineralizing media and maintained in
regular conditions for one week. They were then exposed to mineralizing media for another
2 weeks. In some experiments MC3T3-E1 cells were transfected with constructs containing
the full length open reading frame of human FOXO1, FOXO1AAA that has mutated Akt
phosphorylation sites so that it is constitutively active, pcDNA empty vector control, or
pcDNA expressing green fluorescent protein. Plasmids were purchased from Addgene.
MC3T3-E1 cells were plated in 4 chamber slides (104/chamber) and transfected with 1μg
plasmid using Lipofectamine 2000 (Invitrogen). At the indicated time point cells were fixed
in 4% paraformaldehyde and visualized for green fluorescent protein or nuclei. Transfection
efficiency was greater than 80% (data not shown). Cells were stained with DAPI to
determine cell number or incubated with antibody to PCNA purchased from (Santa Cruz
Biotechnology (Santa Cruz, CA). The number of PCNA positive cells was determined
following incubation with a biotinylated secondary antibody (Millipore, Billerica, MA) and
streptavidin Alexa 546 (Invitrogen). In some experiments apoptosis was detected using a
Dead End Fluorometric TUNEL kit (Promega, Madison, WI) following the manufacturer's
instructions. Images were captured using Nikon Eclipse 90i Instrument (Nikon Instruments
Inc., Melville, NY). Cells were counted using NIS-Elements Microscope Imaging Software
(Nikon Instruments Inc.) in a blind fashion.
Lentivirus
Lentiviral constructs utilized the third generation, self-inactivating, replication incompetent
lentiviral backbone vector pLVTHM, [16], a generous gift of the laboratory of Prof. Didier
Trono (University of Geneva, Switzerland). The pLVTHM vector was modified for
knockdown of FoxO1 by a short hairpin RNA (shRNA) designed to target the FoxO1 cDNA
sequence CGGAGGATTGAACCAGTATAA. A second control shRNA without known
mammalian gene target) was designed as a negative (non-targeting) control,
TGACGACGAGCGCTCCTACAG. Vesicular stomatitis virus (VSV) pseudotyped
lentiviral particles were generated by transfection of 293T cells with the lentiviral back-bone
construct together with four helper plasmids encoding the viral genes Gag-Pol, Tat, Rev, and
VSV-G [17]. Titers of fluorochrome-expressing lentiviruses were calculated as “293-
transducing units” per ml (TU/ml) based on flow cytometry of infected 293 cells. MC3T3-
E1 cells were maintained for 2 days in mineralizing media, and then infected at a
multiplicity of infection (MOI) of 40 for 6 hours using hexadimethrine bromide after which
cells continued incubation in mineralizing culture media. In some experiments cells were
checked 96 hours after transduction for expression of green fluorescence protein (GFP) to
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observe the efficiency of the transduction. Cells were maintained in mineralizing media for a
total of 2 weeks.
Protein Extraction and Function
At specific time points cytoplasmic and nuclear proteins were extracted with the NE-PER
Nuclear and Cytoplasmic Extraction Reagents (Pierce Biotechnology, Rockland, IL) and
Halt Protease Inhibitor Cocktail (Pierce Biotechnology) following the manufacturer's
instructions. Protein concentrations were determined by BCA (Pierce Biotechnology). The
nuclear fraction was assayed for FOXO1 and RUNX2 DNA binding activity (Active Motif)
following the manufacturer's instructions. The cytoplasmic fraction was tested for alkaline
phosphatise activity using AP assay reagent A (GenHunter Corporation, Nashville, TN).
RNA Isolation and quantification by Real-time PCR
During selected time points total RNA was extracted and purified using QIAshredder spin
columns (Qiagen, Valencia, CA) and the RNeasy Mini Kit (Qiagen), following the
manufacturer's instructions. Reverse transcriptase reaction was performed with the use of
MultiScribe Reverse Transcriptase Kit purchased from Applied Biosystems (Foster City,
CA) and Real-time PCR was carried out with gene specific primers and normalized by the
housekeeping gene RPL32 (Applied Biosystems). Osteocalcin mRNA levels were assessed
with SYBR Green labeled primers with the sequence: 5′-
GCAATAAGGTAGTGAACAGACTCC-3′ and 5′-AGCAGGGTTAAGCTCACACTG-3′
and was normalized to ß-actin with the sequence: 5′-GCTCTTTTCCAGCCTTCCTT-3′ and
5′-AGGTC TTTACGGATGTCAACG-3. An Osteogenesis Focused DNA Microarray
(Oligo GEArray), purchased from SABiosciences (Frederick, MD) was carried out to
characterize gene expression.
Mineralized Nodule Formation
After 21 days in culture cells were fixed with 10% phosphate-buffered formalin (Electron
Microscopy Sciences, Hatfield, PA) and stained with alizarin red [18, 19]. The nodule
number and size were analyzed by Image Pro Plus software (MediaCybernetics, Bethesda,
MD). Alizarin red staining was eluted and the acid soluble calcium measured at OD 415 nm.
Statistical Analysis
Statistical analysis was assessed by One Way ANOVA with Scheffe's post-hoc for
comparisons between multiple groups and students t-test test for comparisons between two
groups, with significance set at P <0.05. The data are presented as the fold maximum and
expressed as mean ± standard error (SEMs). In all assays, three independent experiments
were carried out with the exception of the chromatin immunoprecipitation assay that was
performed twice independently with consistent results. For microarrays three independent
sets of cells were stimulated, RNA was combined and three sets of microarrays were carried
out separately.
Results
To explore the role of FOXO1 in osteoblast differentiation, FOXO1 DNA binding and
FOXO1 mRNA were examined in MC3T3-E1 cells cultured under mineralizing conditions
(Fig. 1A and B). FOXO1 mRNA levels were not significantly higher on day 7 but were
increased 2.2 fold (P <0.05) after 14 days when compared to day zero. FOXO1 DNA
binding activity to an oligonucleotide consensus sequence, measured by ELISA, increased
1.7 fold on day 7 and 2.5 fold on day 14 (P <0.05) when compared to day zero. To
functionally examine the impact of FOXO1, RNAi experiments were carried out. Pilot
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studies were conducted to determine both the length of time and degree of knockdown that
could be achieved, and a dose of 5 nM of siRNA was selected (data not shown). FOXO1-
specific siRNA when compared to scrambled siRNA reduced DNA binding by 50% (P
<0.05) after 14 days. The positive control, excess unlabelled probe, reduced FOXO1 DNA
binding by 62% (P <0.05), while non-specific probe had no effect (P >0.05). FOXO1
siRNA reduced FOXO1 mRNA levels by 48% on day 14 (P <0.05) (Fig.1B). Thus, FOXO1
siRNA had a significant effect for a relatively long period of time consistent with other
reports that siRNA can cause extended knockdown of target genes including mineralizing
cultures of MC3T3 cells [19, 20].
Since RUNX2 plays an important role in osteoblast differentiation the effect of FOXO1
knock down on RUNX2 DNA binding activity and mRNA levels were examined. MC3T3-
E1 cells were transfected with FOXO1 siRNA or scrambled siRNA and nuclear protein and
total RNA was obtained. RUNX2 DNA binding activity was approximately 2 fold increased
at 14 days when compared to day zero (P <0.05), which decreased approximately 50% with
FOXO1 knockdown (P <0.05) (Fig.2A). When the mRNA level of RUNX2 was accessed,
an increase of 2.5 fold was found on day 7 (P <0.05) and an increase of 7 fold (P <0.05) was
obtained on day 14 when compared to day zero. When FOXO1 was knocked down, RUNX2
expression decreased 55% (P <0.05) on day 14 when compared to scrambled siRNA (Fig.
2B).
To determine whether FOXO1 targets the RUNX2 gene directly during differentiation, the
endogenous RUNX2 promoter was probed in chromatin immunoprecipitation (ChIP) assays
in differentiating MC3T3-E1 cells. Promoter occupation by the transcription factor Sp1 was
used as a reference point based on a recent report that it associates with the RUNX2
promoter during the early, proliferative phase of these cultures [21]. Sp1 was present on the
RUNX2 promoter in the committed pre-osteoblast stage prior to differentiation (day 0), but
not at later time points (days 7 and 14). In contrast FOXO1 association with the RUNX2
promoter was not detected at the zero time point. However, there was interaction on days 7
and 14 consistent with an association during differentiation. These findings reveal important
dynamics in RUNX2 targeting by FOXO1.
Alkaline phosphatase activity and mRNA levels of type I collagen, osteocalcin and MMP13
were examined since they are known to be highly expressed in differentiated osteoblasts.
Alkaline phosphatase activity showed an increase of 2 fold on day 7 (P <0.05) and 3.5 fold
on day 14 (P <0.05) when compared to day zero. The effect of FOXO1 knockdown on day 7
was not significant but FOXO1 siRNA reduced alkaline phosphatase activity by 53% (P
<0.05) on day 14 compared to scrambled siRNA (Fig.3A). At the mRNA level, type I
collagen exhibited at 3.5 fold increase on day 14 (P <0.05) when compared to day zero and
was reduced by 40% (P <0.05) on day 14 by FOXO1 siRNA when compared to scrambled
siRNA (Fig. 3B). Osteocalcin mRNA levels increased 50 fold (P <0.05) on day 14 and the
knockdown of FOXO1 reduced osteocalcin mRNA levels on day 14 by 40% (P <0.05) (Fig.
3C). MMP13 mRNA levels increased ∼50 fold (P <0.05) on day 14 and were reduced by
44% (P <0.05) in cultures incubated with FOXO1 siRNA when compared to scrambled
siRNA (Fig. 3D).
mRNA levels of a number of genes that reflect osteoblast differentiation were measured in a
focused osteogenesis microarray. MC3T3-E1 cells were cultured in mineralizing media for
14 days and compared to cells collected at day zero to determine changes in osteogenic gene
expression in mineralizing cultures. To examine the role of FOXO1 in osteoblast
differentiation, day 14 cultures that had been transfected with FOXO1 siRNA were
compared to those transfected with scrambled siRNA (Table 1). The results showed that
80% of the genes present in the array were up-regulated in the mineralized cultures when
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compared to day zero and it included genes that control osteoblast differentiation such as
transcription factors RUNX2, SMAD5 and SMAD7 and bone morphogenetic proteins
BMP2, BMP5 and BMP8a, as well as genes that reflect differentiated osteoblast function
such as extracellular matrix proteins MMP13, MMP2, MMP9, Col4a4, Col4a3, Col1a1 and
Col9a1. Induction of many of these genes was impaired in FOXO1-depleted cells, including
RUNX2, SMAD5, SMAD7, BMP2, BMP5, BMP8a, MMP13, MMP9, Col4a4, Col4a3,
Col1a1 and Col9a1, which states the significance of FOXO1 in the regulation of osteogenic
gene expression during osteoblast differentiation. A broad range of osteogenic genes is
dependent on FOXO1, and FOXO1 acts directly at the major control point represented by
RUNX2 induction.
MC3T3-E1 cells have the capacity to form mineralized nodules upon stimulation with
ascorbic acid and β-glycerolphosphate [22, 23]. MC3T3-E1 cells were transfected with
FOXO1 siRNA or scrambled siRNA and treated in mineralizing media as described above.
Mineralized nodules were assessed after 21 days in culture by staining with alizarin red. The
stain was eluted and the acid soluble calcium bound dye was quantified (Fig. 4A). Nodules
were formed as expected by the mineralization group. Scrambled siRNA had no effect on
the formation of a calcified matrix. In contrast, FOXO1 siRNA reduced mineralized matrix
formation by approximately 50% when compared to scrambled siRNA (P <0.05). In
parallel, the number of nodules was counted; reflecting differentiation of precursors to
mature osteoblastic cells (Fig. 3B), the total nodule area was measured (Fig. 3C) and the
area per nodule was accessed to reflect the impact on growth of nodules (Fig. 3D). Results
indicate that FOXO1 knockdown reduced the number of nodules by approximately 50% and
the total area of mineralized nodules was also reduced by approximately 50% (P <0.05).
However, no difference was found in the average area per nodule with FOXO1 knock down
(P >0.05).
A second approach was taken to confirm the sustained knock down of FOXO1 after 14 days
using stable transduction with lentiviral constructs that expressed FOXO1 shRNA or
scrambled shRNA. MC3T3-E1 cells were transduced with lentiviral vector and incubated in
mineralizing media. GFP was detected only in transduced cells and showed transduction
efficiency close to 100% (Fig. 5A). mRNA was examined for real-time PCR to assess the
expression levels of FOXO1 knock down as well as the impact of FOXO1 knockdown on
RUNX2 and osteocalcin mRNA levels (Fig. 5B-D). FOXO1 mRNA levels increased 1.7
fold (P <0.05) after 14 days in mineralizing media and were 52% decreased (P <0.05) with
FOXO1 shRNA (Fig.5B). When RUNX2 was tested an increase of 3 fold was obtained after
14 days of culture in mineralizing media (P <0.05) and a reduction of 51% by FOXO1
shRNA when compared to scrambled shRNA (P <0.05) (Fig.5C). Osteocalcin showed an
increase of 100 fold after 14 days of culture in mineralizing media and a reduction of 69%
by FOXO1 shRNA when compared to scrambled shRNA (P <0.05) (Fig.5D).
Since FOXO1 has been reported to affect proliferation by inhibiting DNA synthesis we
examined the effect of FOXO1 over-expression on MC3T3 cell number (Fig 6). Cells were
transfected with a vector expressing GFP as a negative control or a plasmid expressing wild-
type or mutated FOXO1 that was constitutively active, FOXO1AAA. Transfection with
control GFP plasmid resulted in a decreased number of cells on days 5 and 7, most likely
due to the effects of transfection per se. Cells with over-expression of GFP increased 140%
over this time period while cells transfected with FOXO1 increased only 43% and with
FOXO1AAA only 15%. Thus FOXO1 significantly reduced cell number. To distinguish
whether changes in cell number were due to effects of FOXO1 on DNA synthesis versus
apoptosis the number of PCNA positive and TUNEL positive cells was determined (Table
2). The number of PCNA positive cells were reduced approximately 90% when cells were
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transfected with FOXO1 or FOXO1AAA compared to vector control (P <0.05). In contrast,
FOXO1 overexpression had no significant effect on the number of TUNEL positive cells.
Discussion
MC3T3-E1 pre-osteoblastic cells undergo differentiation and formation of a mineralizing
matrix. These cell cultures are frequently used to investigate the role of specific genes in
osteoblast differentiation. In this study, knocking down FOXO1 with siRNA or by viral
transduction with shRNA showed that FOXO1 plays an important role in promoting
osteoblast differentiation. When FOXO1 was depleted, multiple markers of osteoblast
differentiation were significantly reduced including mRNA levels of collagen 1, RUNX2,
osteocalcin and MMP13. FOXO1 siRNA significantly reduced the up-regulation of alkaline
phosphatase activity that occurs as a result of osteoblast differentiation. These results are
unlikely to be due to global changes since FOXO1 knockdown did not affect that overall
protein or total RNA levels per well (data not shown). Additional evidence that FOXO1
promotes osteoblast differentiation is the reduction in the number of mineralized nodules
that formed when FOXO1 was targeted by siRNA. This biological parameter reflects
terminal differentiation of osteoblasts from precursors.
FOXO1 knockdown sharply reduced RUNX2 mRNA levels, indicating that FOXO1 acts
upstream of RUNX2 induction. The possibility that the biochemical mechanism of FOXO1
effects on osteoblast differentiation includes direct targeting of the RUNX2 gene was
confirmed in ChIP assays, which indicate that FOXO1 targets the RUNX2 promoter
directly, and with dynamics that correlate specifically with induction of differentiation. The
reduction of RUNX2 mRNA levels was accompanied by a decrease in RUNX2 DNA
binding activity, implying that direct targeting of downstream osteogenic genes by RUNX2
is impaired concordant with depletion of FOXO1. The results do not rule out the possibility
that there are multiple mechanisms by which FOXO1 directly or indirectly modulates
RUNX2 activity and expression of osteogenic genes, but they establish an early, direct, and
essential role for FOX01 in osteoblast differentiation. This is underscored by the relatively
large number of genes that were modulated by FOXO1 knockdown, which included
transcription factors, enzymes associated with differentiated function, bone morphogenetic
proteins, and extracellular matrix proteins.
FOXO1 has been shown to affect differentiation of adipocytes [24, 25]. Constitutively active
FOXO1 inhibits the differentiation of pre-adipocytes into mature adipocytes, while a
dominant-negative FOXO1 enhances adipocyte differentiation [24]. Interestingly,
adipocytes and osteoblasts share similar precursors and tend to be differentially regulated so
that inhibition of adipocyte differentiation is associated with promotion of osteoblast
differentiation [26]. Thus, FOXO1 could preferentially modulate precursors toward an
osteoblastic phenotype and away from an adipocyte pathway.
We found that upregulated expression of osteocalcin during osteoblast differentiation was
significantly reduced when FOXO1 was targeted by siRNA or shRNA. This is consistent
with a report that FOXO1 regulates osteocalcin expression and thereby affects energy
regulation [27]. FOXO1 has previously been reported to contribute to apoptosis of bone-
lining cells. Activation of a vigorous immune response in close proximity to bone leads to
FOXO1-mediated apoptosis of bone cells [28], with a net negative effect on bone formation.
Deletion of FOXO1, FOXO3 and FOXO4 has recently been reported to inhibit osteoblast
differentiation, indirectly suggesting that FOXO1 has a positive effect on promoting
differentiation (14). Our results provide direct support for this concept, showing that
knockdown of FOXO1 interferes with differentiation of osteoblastic cells from committed
precursors. Another publication has indicated that FOXO1 promotes bone formation by
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protecting osteoblasts from oxidative stress and increases osteoblast proliferation (13).
However, we found that FOXO1 overexpression in MC3T3-E1 cells reduced proliferation. It
is possible that this apparent discrepancy is due to the approach used or that FOXO1 has
different effects on proliferation depending on the degree of osteoblast differentiation. It
should be noted that in most cell types FOXO1 inhibits proliferation [29]. In summary, the
present study suggests that FOXO1 is an important transcription factor that interacts with the
RUNX2 promoter and promotes osteoblast differentiation and differentiation-associated
cessation of proliferation.
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Figure 1. FOXO1 DNA binding activity and mRNA levels are increased in mineralizing cultures
of osteoblastic cells and knocked down by FOXO1 siRNA
MC3T3-E1 cells were cultured under mineralizing conditions and transfected with either
FOXO1 specific or scrambled siRNA. Nuclear protein or total RNA was isolated 0, 7 and 14
days later. (A) FOXO1 DNA binding activity was measured. A subset of the 14 day samples
included excess competitive oligonucleotide (comp.) or excess non-competitive
oligonucleotide (non-comp.). (B) FOXO1 mRNA levels were measured by real time PCR
and normalized to ribosomal protein L32. The data presented are the means of three
independent experiments ± SEM and are shown as the fraction of maximum stimulation.
Asterisks indicate significantly increased values compared to day zero and double asterisks
indicate significant reduction of FOXO1siRNA transfected cells compared to scrambled
siRNA (P < 0.05).
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Figure 2. RUNX2 levels are reduced by FOXO1 knockdown and FOXO1 interacts with the
RUNX2 promoter
MC3T3-E1 cells were cultured under mineralizing conditions and transfected with either
FOXO1 specific or scrambled siRNA. After 0, 7 and 14 days nuclear protein and total RNA
were extracted. (A) RUNX2 DNA binding was assessed. (B) RUNX2 mRNA levels were
measured by real time PCR and normalized to ribosomal protein L32. For (A) and (B) the
data presented are the mean of three independent experiments ± SEM and are shown as the
fraction of maximum stimulation. Asterisks indicate significantly increased values compared
to day zero and double asterisks indicate significant reduction of cells transfected with
FOXO1 siRNA compared to scrambled siRNA (P < 0.05). (C) DNA was isolated from
MC3T3-E1 cells after 0, 7, and 14 days of culture in mineralizing media. Nuclear lysates
were examined by chromatin immunoprecipitation (ChIP) with antibodies to FOXO1 and
Sp1 as indicated. Input DNA and DNA immunoprecipitated with non-specific IgG were
included as positive and negative controls, respectively. The results are representative of two
independent experiments. (D) Schematic representation of the 5′ untranslated region of
murine RUNX2. The numbering system was adapted from reference 21. The promoter
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sequence was analyzed using the PROMO website.
(http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) Squares
represent the location of five predicted FOXO1 binding sites (I –V). The open circles (C,D)
represent the location of SP1 binding sites predicted by PROMO. The shaded circles (A,B)
represent additional potential SP1 sites (21). Arrows indicate the location of the primers
used in the ChIP analysis.
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Figure 3. Knockdown of FOXO1 inhibits up-regulation of markers of osteoblast differentiation
MC3T3-E1 cells were maintained under mineralizing conditions and transfected with either
FOXO1 specific or scrambled siRNA. After 0, 7 and 14 days cytoplasmic protein and total
RNA were obtained. (A) Alkaline phosphatase activity was measured. (B-D) mRNA levels
of Type 1 collagen, osteocalcin, and MMP13 were analyzed by real time PCR and
normalized to ribosomal protein L32. The data presented are the mean of three independent
experiments ± SEM and are shown as the fraction of maximum stimulation. Asterisks
indicate significantly increased values compared to day zero and double asterisks indicate
significant reduction compared to cells treated with scrambled siRNA (P < 0.05).
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Figure 4. The formation of mineralized nodules is reduced by FOXO1 knockdown
(A-D) MC3T3-E1 cells were transfected with either FOXO1 specific or scrambled siRNA
and cultured under mineralizing conditions. After 21 days cells were stained with Alizarin
red. (A) Acid soluble-calcium was measured spectrophotometrically and is presented as the
fraction of maximum stimulation. (B) The total number of nodules was counted. (C) The
total nodule area was measured. (D) The average area per nodule was quantified. The data
are the mean of three independent experiments ± SEM. Asterisks indicate significantly
reduced values compared to cells treated with scrambled siRNA (P < 0.05).
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Figure 5. Lentiviral mediated FOXO1 shRNA reduces FOXO1, RUNX2 and osteocalcin mRNA
levels
MC3T3-E1 cells were transduced with lentiviral constructs expressing GFP and FOXO1
shRNA or scrambled shRNA. After 14 days of culture in mineralizing media GFP was
detected by immunofluorescence and total RNA isolated. The mRNA levels of FOXO1,
RUNX2 and osteocalcin were measured by real time PCR and normalized to ribosomal
protein L32. (A) GFP detection in transduced cells. (B) FOXO1 mRNA levels. (C) RUNX2
mRNA levels. (D) Osteocalcin mRNA levels. The data presented are the mean of three
independent experiments ± SEM and are shown as the fraction of maximum stimulation.
Asterisks indicate significantly increased values compared to day zero and double asterisks
indicate significant reduction.
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Figure 6. Overexpression of FOXO1 reduces proliferation
MC3T3-E1 cells were transfected with GFP-pcDNA, FOXO1 or FOXO1AAA and cultured
from 0 to 7 days. Cells were stained with DAPI and the number of cells per field was
counted with a fluorescence microscope. The data presented are the mean of three
independent experiments ± SEM. Asterisks indicate significantly increased values compared
to no treatment, double asterisks indicate significant reduction compared to cells treated with
transfected with GFP-pcDNA (P < 0.05).
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Table 1
Focused osteogenic microarray
Fold Change Induced by Differentiation Fold Change in FOXO1 vs. Scrambled siRNA in Differentiated Cultures
Gene Name Mean Median Mean Median
Mmp13 5.40 4.99 0.41 0.49
Itgav 3.88 3.92 0.39 0.45
Ibsp 3.78 3.75 0.92 0.82
Fgf2 3.77 4.10 0.41 0.42
Col11a1 3.59 2.99 0.48 0.51
Gdf10 3.57 3.44 0.52 0.58
Col12a1 3.27 3.28 0.35 0.35
Dcn 3.23 3.13 0.62 0.63
Col18a1 3.15 2.86 0.44 0.45
Itga3 3.13 3.02 0.42 0.46
Phex 3.10 3.08 0.41 0.49
Fgf1 3.09 3.17 0.41 0.41
Msx1 3.06 2.49 0.41 0.39
Col4a4 2.99 2.82 0.37 0.38
Col19a1 2.93 2.72 0.39 0.39
Bmp6 2.91 2.92 0.37 0.35
Bmp8b 2.90 2.95 0.34 0.33
Mmp8 2.89 3.14 0.41 0.44
Bmp2 2.89 2.78 0.32 0.34
Ambn 2.84 2.93 0.41 0.37
Csf2 2.83 2.96 0.43 0.45
Bmpr1a 2.82 2.73 0.37 0.39
Cd36 2.82 2.86 0.38 0.38
Fgfr1 2.81 2.74 0.42 0.37
Comp 2.81 2.61 0.40 0.40
Col2a1 2.80 2.44 0.53 0.54
Col4a3 2.80 2.89 0.42 0.43
Bmp5 2.76 2.86 0.35 0.37
Col14a1 2.75 2.84 0.38 0.36
Dmp1 2.74 2.41 0.53 0.46
Calcr 2.73 2.85 0.36 0.38
Bmp7 2.70 2.67 0.40 0.39
Itgam 2.69 2.42 0.40 0.41
Fgf3 2.69 2.71 0.43 0.37
Bmp8a 2.68 2.54 0.40 0.43
Bmpr1b 2.67 2.60 0.35 0.34
Egf 2.66 2.58 0.40 0.42
Fgfr3 2.64 2.64 0.42 0.42
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Fold Change Induced by Differentiation Fold Change in FOXO1 vs. Scrambled siRNA in Differentiated Cultures
Gene Name Mean Median Mean Median
Akp2 2.62 2.26 0.50 0.59
Col1a1 2.61 2.63 0.43 0.44
Col9a1 2.58 2.68 0.49 0.56
Col4a6 2.58 1.82 0.47 0.50
Dspp 2.57 1.92 0.58 0.53
Runx2 2.56 2.57 0.44 0.43
Col10a1 2.54 2.11 0.51 0.51
Enam 2.54 2.33 0.49 0.46
Mmp2 2.50 3.04 0.71 0.80
Smad7 2.49 2.53 0.40 0.40
Bmp1 2.45 2.44 0.46 0.46
Itga2 2.43 2.43 0.45 0.50
Tgfbr3 2.42 1.87 0.54 0.64
Itga2b 2.40 1.70 0.65 0.75
Col15a1 2.36 2.34 0.54 0.45
Smad9 2.35 2.26 0.43 0.39
Mmp9 2.31 2.21 0.54 0.54
Tnf 2.30 2.14 0.52 0.62
Fgfr2 2.30 2.24 0.45 0.42
Sost 2.29 2.30 0.44 0.45
Ctsk 2.27 2.43 0.65 0.41
Col6a2 2.26 2.19 0.61 0.45
Smad5 2.26 2.21 0.44 0.42
Smad6 2.26 2.25 0.43 0.45
Anxa5 2.24 2.82 0.82 0.75
Tgfb1 2.24 2.29 0.43 0.40
Bmp3 2.23 2.16 0.45 0.53
Icam1 2.22 2.15 0.44 0.45
Col7a1 2.22 2.64 0.50 0.45
Tgfbr1 2.21 2.16 0.42 0.42
Flt1 2.20 1.84 0.68 0.53
Col4a2 2.17 1.73 0.60 0.53
Vegfa 2.14 1.93 0.48 0.47
Bmp4 2.12 2.29 0.51 0.56
Tuft1 2.12 2.14 0.51 0.41
Col3a1 2.12 1.83 1.13 0.60
Smad4 2.06 1.78 0.46 0.52
Smad1 2.00 1.87 0.44 0.44
Csf3 1.99 1.91 0.57 0.62
Cdh11 1.92 1.74 0.70 0.63
Smad3 1.91 1.71 0.54 0.55
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Fold Change Induced by Differentiation Fold Change in FOXO1 vs. Scrambled siRNA in Differentiated Cultures
Gene Name Mean Median Mean Median
Tfip11 1.91 1.87 0.46 0.46
Twist2 1.91 1.81 0.43 0.41
Col4a1 1.90 1.53 0.73 0.70
Col9a3 1.90 1.29 0.69 0.77
Bmpr2 1.85 1.72 0.61 0.58
Fn1 1.85 2.02 0.82 0.84
Serpinh1 1.85 1.15 0.72 0.88
Igf1 1.81 1.84 0.60 0.53
Ahsg 1.74 1.57 0.51 0.62
Mmp10 1.73 1.72 0.59 0.70
Tgfb2 1.71 1.95 0.49 0.44
Igf1r 1.69 1.77 0.54 0.51
Tgfb3 1.64 1.30 0.71 0.81
Twist1 1.60 1.44 0.66 0.68
Scarb1 1.55 1.06 0.69 0.84
Sox9 1.53 1.23 0.77 0.89
Vdr 1.53 1.36 0.55 0.59
Smad2 1.52 1.32 0.57 0.68
Vegfb 1.48 1.32 0.72 0.74
Col6a1 1.47 0.69 1.01 0.84
Col8a1 1.47 1.35 1.00 0.83
Itgb1 1.46 1.35 0.67 0.69
Vegfc 1.44 1.39 0.53 0.56
Col4a5 1.40 1.24 0.66 0.55
Pdgfa 1.38 1.55 0.93 0.72
Nfkb1 1.37 1.30 0.67 0.61
Col1a2 1.32 1.35 0.91 0.91
Mgp 1.30 1.37 0.84 0.73
Tgfbr2 1.29 1.18 0.67 0.74
Vcam1 1.25 1.04 0.78 0.92
Col5a1 1.09 1.11 0.91 0.85
Spp1 1.02 0.87 0.95 0.85
Bgn 0.90 0.95 1.70 1.07
Sparc 0.77 0.99 1.61 0.83
MC3T3-E1 cells were maintained under mineralizing conditions. In some cases cells were transfected with either FOXO1 specific or scrambled
siRNA. At day zero and day 14 total RNA was isolated and an osteogenic focused microarray was carried out. The data presented are the mean and
median of three microarrays carried out per assay condition and compared to the matching control. Values in bold illustrate changes where mean
and median values demonstrated a minimum of 1.7 fold increase or 0.6 fold decrease (corresponding to 1.7 fold decrease). Thus the mean fold
change met a minimum threshold and the median values ensure that not less than two out of the three microarrays independently met this threshold.
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Table 2
Overexpression of FOXO1 reduces the number of PCNA positive cells but not TUNEL
positive cells
PCNA positive (percent) TUNEL positive (percent)
No treatment 83 ± 3.2 0.33 ± 0.01
Vector control (pcDNA) 69.3 ± 8.6 0.9 ± 0.01
FOXO1 6.3 ± 1.3* 0.8 ± 0.01
FOXO1AAA 7.3 ± 3.4* 0.43 ± 0.01
MC3T3-E1 cells were transfected with control vector, FOXO1 or FOXO1AAA and cultured for 5 days. PCNA positive cells were measured by
immunohistochemistry and apoptosis was assessed by the TUNEL Assay. Data are expressed as the percent positive cells and are the mean of three
independent experiments ± SEM. Asterisk indicates significant reduction of cells compared to vector control (P < 0.05).
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